To demonstrate the in vivo tumor-targeting properties of trastuzumab-IFN-β mutein depend on whether HER2 is expressed or not, fluorescence imaging assay was conducted in xenograft mice bearing tumors with HER2 positive (NCI-N87) or negative (Hs746T). Here, ERBB2 is linked to neoplasm.